Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidate

/ / News

Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 clinical trial for its COVID-19 vaccine candidate. Arcturus last week announced disappointing data from the Phase 1/2 trial conducted in Singapore that sent the stock tumbling 55%. The Phase 2 trial, which will be conducted in Singapore and the U.S., will test a single dose and two-dose regimen in about 600 participants. The company said it expects interim data from the study to be shared publicly in “early 2021.” Arcturus’ stock has soared 336.4% over the last year, while the S&P 500 is up 16.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.